NovaBridge Biosciences Increase (Decrease) in Accounts Payable and Accrued Liabilities
NovaBridge Biosciences (NBP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $18.08 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-04-07
- NovaBridge Biosciences increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2020-12-31 was 191.34M CNY, a 22.51% increase year-over-year.
- NovaBridge Biosciences increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-12-31 was 156.18M CNY.
CNY
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | -342.71M CNY 20-F · filed 2024-04-30 | |||
| 2022-12-31 | 109.86M CNY 20-F · filed 2024-04-30 | |||
| 2022-06-30 | -49.09M CNY 6-K · filed 2022-11-10 | |||
| 2021-12-31 | 152.10M CNY 20-F · filed 2024-04-30 | |||
| 2021-06-30 | 104.49M CNY 6-K · filed 2022-11-10 | |||
| 2020-12-31 | 191.34M CNY derived: 20-F 12 month − 6-K 9 month · filed 2023-05-01 | 173.71M CNY 20-F · filed 2023-05-01 | ||
| 2020-09-30 | -17.62M CNY 6-K · filed 2021-02-05 | |||
| 2019-12-31 | 156.18M CNY derived: 20-F 12 month − 6-K 9 month · filed 2022-04-29 | 188.38M CNY 20-F · filed 2022-04-29 | ||
| 2019-09-30 | 32.20M CNY 6-K · filed 2021-02-05 | |||
| 2018-12-31 | 55.64M CNY 20-F · filed 2021-04-28 | |||
| 2017-12-31 | 408.00K CNY 20-F · filed 2020-04-29 |
USD
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.71M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | $19.34M derived: sum of 2 quarters · filed 2026-04-07 | $18.08M 20-F · filed 2026-04-07 | ||
| 2025-09-30 | $8.64M derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $7.38M 6-K · filed 2025-12-18 | |||
| 2025-06-30 | -$1.26M 6-K · filed 2025-10-06 | ||||
| 2024-12-31 | -$3.31M derived: 20-F 12 month − 6-K 9 month · filed 2026-04-07 | -$3.55M derived: sum of 2 quarters · filed 2026-04-07 | -$213.00K 20-F · filed 2026-04-07 | ||
| 2024-09-30 | -$240.00K derived: 6-K 9 month − 6-K 6 month · filed 2025-12-18 | $3.10M 6-K · filed 2025-12-18 | |||
| 2024-06-30 | $3.34M 6-K · filed 2025-10-06 | ||||
| 2023-12-31 | -$35.68M 20-F · filed 2026-04-07 | -$48.27M 20-F · filed 2024-04-30 | |||
| 2022-12-31 | $18.34M 20-F · filed 2025-04-03 | $15.93M 20-F · filed 2023-05-01 | |||
| 2022-06-30 | -$7.33M 6-K · filed 2022-11-10 | ||||
| 2021-12-31 | $23.87M 20-F · filed 2022-04-29 | ||||
| 2020-12-31 | $29.22M derived: 20-F 12 month − 6-K 9 month · filed 2021-04-28 | $26.62M 20-F · filed 2021-04-28 | |||
| 2020-09-30 | -$2.60M 6-K · filed 2021-02-05 | ||||
| 2019-12-31 | $27.06M 20-F · filed 2020-04-29 |